Idexx Laboratories Inc /De IDXX

Revenue Intelligence Report • 66 quarters of SEC filing data • Updated 2026-03-06

Idexx Laboratories Inc demonstrates a unique revenue generation model where its SG&A spending yields a robust long-run revenue return of $21.40 for every dollar invested, while R&D spending shows a negative impact on revenue. The company's latest quarterly revenue of $1,091 million reflects strong performance, with a forecasted FY revenue of $5 billion, representing a 6.9% year-over-year growth. With a low model accuracy error of just 2.7% MAPE and a holdout test error of 1.5%, investors can be confident in the reliability of the company's revenue projections. Overall, Idexx is positioned for continued growth, driven primarily by its efficient SG&A expenditures.

Next FY Revenue

$4.60B

+6.9% YoY

R&D Multiplier

$-77.52 per $1

SG&A Multiplier

$21.40 per $1

Model Accuracy

2.7% MAPE

Holdout validation: The model predicted $1B vs the actual $1B — an error of 1.5%.

⚠ Model limitation: This company shows negative spending multipliers, meaning increases in spending have not directly translated into revenue growth. This typically occurs with commodity-driven companies or hypergrowth companies.

Revenue Forecast

Quarterly Detail

Quarter	Model Forecast	Actual	95% Range	YoY Growth	Status
Q4 2025	$1B	$1B	$1B – $1B	+12.5%	✓ In range
Q2 2026	$1B		$1B – $1B	+9.1%
Q3 2026	$1B		$1B – $1B	+3.7%
Q4 2026	$1B		$1B – $1B	+6.9%
Q1 2027	$1B		$1B – $1B	+8.0%

How Spending Drives Revenue

Reading this chart: Each line shows the cumulative revenue generated per $1 spent over subsequent quarters. The effect builds over 4-5 quarters as investments mature.

Want this analysis for your portfolio?

I build custom revenue intelligence reports for investors and companies using SEC filing data, econometric modeling, and AI-powered insights.

Get in Touch